420 related articles for article (PubMed ID: 27062333)
1. Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer.
Chung SD; Lin HC; Tsai MC; Kao LT; Huang CY; Chen KC
Andrology; 2016 May; 4(3):481-5. PubMed ID: 27062333
[TBL] [Abstract][Full Text] [Related]
2. No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.
Kao LT; Lin HC; Chung SD; Huang CY
Asian J Androl; 2017; 19(4):414-417. PubMed ID: 27232853
[TBL] [Abstract][Full Text] [Related]
3. Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.
Nead KT; Gaskin G; Chester C; Swisher-McClure S; Dudley JT; Leeper NJ; Shah NH
J Clin Oncol; 2016 Feb; 34(6):566-71. PubMed ID: 26644522
[TBL] [Abstract][Full Text] [Related]
4. Hormone therapy for prostate cancer increases the risk of Alzheimer's disease: a nationwide 4-year longitudinal cohort study.
Jhan JH; Yang YH; Chang YH; Guu SJ; Tsai CC
Aging Male; 2017 Mar; 20(1):33-38. PubMed ID: 28067607
[TBL] [Abstract][Full Text] [Related]
5. No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men.
Wang LH; Liu CK; Chen CH; Kao LT; Lin HC; Huang CY
Andrology; 2016 Jan; 4(1):128-32. PubMed ID: 26711703
[TBL] [Abstract][Full Text] [Related]
6. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
7. Androgen Deprivation Therapy Use Increases the Risk of Heart Failure in Patients With Prostate Cancer: A Population-Based Cohort Study.
Kao HH; Kao LT; Li IH; Pan KT; Shih JH; Chou YC; Wu ST
J Clin Pharmacol; 2019 Mar; 59(3):335-343. PubMed ID: 30402905
[TBL] [Abstract][Full Text] [Related]
8. Hormone therapy for prostate cancer and the risk of stroke: a 5-year follow-up study.
Chung SD; Chen YK; Wu FJ; Lin HC
BJU Int; 2012 Apr; 109(7):1001-5. PubMed ID: 21883836
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of a herpes zoster attack in patients receiving androgen deprivation therapy for prostate cancer.
Wu FJ; Kao LT; Sheu SY; Lin HC; Chung SD
Andrologia; 2018 Mar; 50(2):. PubMed ID: 28786220
[TBL] [Abstract][Full Text] [Related]
10. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
Ng HS; Koczwara B; Roder D; Vitry A
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
[TBL] [Abstract][Full Text] [Related]
11. Increased Fall Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer.
Wu FJ; Sheu SY; Lin HC; Chung SD
Urology; 2016 Sep; 95():145-50. PubMed ID: 27318262
[TBL] [Abstract][Full Text] [Related]
12. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.
Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ
Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
14. Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder.
Chung SD; Kao LT; Lin HC; Xirasagar S; Huang CC; Lee HC
PLoS One; 2017; 12(3):e0173266. PubMed ID: 28253340
[TBL] [Abstract][Full Text] [Related]
15. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC
Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178
[TBL] [Abstract][Full Text] [Related]
16. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
[TBL] [Abstract][Full Text] [Related]
17. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer.
Krasnova A; Epstein M; Marchese M; Dickerman BA; Cole AP; Lipsitz SR; Nguyen PL; Kibel AS; Choueiri TK; Basaria S; Mucci LA; Sun M; Trinh QD
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):410-418. PubMed ID: 31784699
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy for prostate cancer and risk of dementia.
Robinson D; Garmo H; Van Hemelrijck M; Damber JE; Bratt O; Holmberg L; Wahlund LO; Stattin P; Adolfsson J
BJU Int; 2019 Jul; 124(1):87-92. PubMed ID: 30637900
[TBL] [Abstract][Full Text] [Related]
20. New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study.
Jhan JH; Yeh HC; Chang YH; Guu SJ; Wu WJ; Chou YH; Li CC
J Diabetes Complications; 2018 Jul; 32(7):688-692. PubMed ID: 29909141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
